Overview

Join Dr Dan Lenihan (Saint Francis Healthcare System, US), Dr Joe Carver (University of Pennsylvania, US), Dr Jose Alvarez-Cardona (New York University School of Medicine, US) and Dr Andrés J. Daniele (Institute of Oncology Angel H. Roffo, AR) as they explore the emerging role of SGLT2 inhibitors in cardio-oncology. 

This expert-led webinar reviews key trial data and clinical strategies to optimise cardio-renal-metabolic care in oncology. Join this month's journal club as clinicians explore the potential of SGLT2 inhibitors to reduce cardiovascular risk in patients receiving cancer treatment.

The partnership combines Radcliffe’s rapidly growing global community and expertise in delivering the most innovative virtual events, with the knowledge and experience of IC-OS’s members, to curate broadcasts that challenge current practice and have real-world patient benefits.

This webinar is for cardiologists, haematologists, oncologists, nurse practitioners, nurses and pharmacists.

The International Cardio-Oncology Society is a committed group of professionals throughout the world who are striving to protect the cardiovascular health of all patients who are undergoing cancer therapy. By optimising the cardiac status of patients with cancer before, during and after their treatment, IC-OS is collectively improving the overall outcomes including survival and quality of life. IC-OS aims to provide the latest scientific and clinical education and research for anyone treating patients with cancer in the hopes of enhancing cardiovascular protection.

This is an independent activity run by the International Cardio-oncology Society (ICOS) and co-produced in collaboration with Radcliffe Cardiology. IC-OS has been provided support to deliver this webinar series by AstraZeneca, BMS/Pfizer Alliance and Sumitomo Pharma through an unrestricted educational grant to cover organisational costs and has had no input into the agenda or content of this educational activity. Radcliffe Cardiology has received no industry funding.